Education
About Us
Working with TipRanks
Follow Us
NeoGenomics Inc. (NEO)
:NEO
NEO Stock Chart & Stats
Day’s Range― - ―
52-Week Range$8.98 - $19.12
Previous CloseN/A
Volume108.49K
Average Volume (3M)1.47M
Market Cap
$1.28B
Enterprise Value$2.31B
Total Cash (Recent Filing)$367.01M
Total Debt (Recent Filing)$605.33M
Price to Earnings (P/E)―
Beta1.44
Next Earnings
May 06, 2025EPS Estimate
>-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.62
Shares Outstanding128,461,380
10 Day Avg. Volume1,432,618
30 Day Avg. Volume1,466,136
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)1.92
Price to Cash Flow (P/CF)32.30
P/FCF Ratio32.30
Enterprise Value/Market Cap1.81
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit7.98
Enterprise Value/Ebitda-1.53K
Forecast
1Y Price Target
$17.78Price Target Upside88.95% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering14
---
NeoGenomics News
See All NEO News
---
Bulls Say, Bears Say
Bulls Say
Acquisition StrategyThe Pathline acquisition helps NeoGenomics Inc. improve its testing capabilities and penetration into the large northeast market.
Growth OutlookThis transaction is consistent with and should help further accelerate NeoGenomics’ growth strategy.
Market Share ExpansionThe acquisition of Pathline is expected to help NEO gain market share from hospital systems and academic medical centers based in the Northeast.
Bears Say
Management ChangesShares of NEO have pulled back by ~30% following the surprising news that the company's CEO, Chris Smith, will leave both the CEO seat and the Board.
Pharma Business ChallengesNEO's pharma business declined by -14% Y/Y in Q4, influenced by funding pressures in biopharma and competitive pressures.
Profitability ConcernsGross margins for the Pathline acquisition are below NeoGenomics Inc.'s average, and revenues per test are expected to temporarily decrease.
---
Ownership Overview
1.05% Insiders
35.45% Mutual Funds
23.47% Other Institutional Investors
14.20% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
NEO FAQ
What was NeoGenomics Inc.’s price range in the past 12 months?
NeoGenomics Inc. lowest stock price was $8.98 and its highest was $19.11 in the past 12 months.
What is NeoGenomics Inc.’s market cap?
NeoGenomics Inc.’s market cap is $1.28B.
When is NeoGenomics Inc.’s upcoming earnings report date?
NeoGenomics Inc.’s upcoming earnings report date is May 06, 2025 which is in 40 days.
How were NeoGenomics Inc.’s earnings last quarter?
NeoGenomics Inc. released its earnings results on Feb 18, 2025. The company reported $0.04 earnings per share for the quarter, beating the consensus estimate of $0.029 by $0.011.
Is NeoGenomics Inc. overvalued?
According to Wall Street analysts NeoGenomics Inc.’s price is currently Undervalued.
Does NeoGenomics Inc. pay dividends?
NeoGenomics Inc. does not currently pay dividends.
What is NeoGenomics Inc.’s EPS estimate?
NeoGenomics Inc.’s EPS estimate is >-0.01.
How many shares outstanding does NeoGenomics Inc. have?
NeoGenomics Inc. has 128,461,380 shares outstanding.
What happened to NeoGenomics Inc.’s price movement after its last earnings report?
NeoGenomics Inc. reported an EPS of $0.04 in its last earnings report, beating expectations of $0.029. Following the earnings report the stock price went down -14.008%.
Which hedge fund is a major shareholder of NeoGenomics Inc.?
Currently, no hedge funds are holding shares in NEO
---
NeoGenomics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$17.78 (88.95% Upside)
$17.78 (88.95% Upside)
Blogger Sentiment
Neutral
NEO Sentiment 50%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 345.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.6%
Last 30 Days ▼ 8.7%
Last 30 Days ▼ 8.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-37.92%
12-Months-Change
Fundamentals
Return on Equity
-8.54%
Trailing 12-Months
Asset Growth
-2.57%
Trailing 12-Months
Company Description
NeoGenomics Inc.
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. It operates through, Clinical Services and Pharma Services segments. The company offers testing services to hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers. It provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. The company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization, as well as acts as a reference laboratory supplying anatomic pathology testing services. It has a strategic alliance agreement and laboratory services agreement with Inivata Limited. The company was founded in 2001 and is headquartered in Fort Myers, Florida.
---
NEO Company Deck
---
NEO Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
NeoGenomics demonstrated strong revenue growth and financial improvement, particularly in its NGS segment and adjusted EBITDA. However, challenges in the pharma segment and ongoing legal issues with RaDaR tempered the overall positive performance.Read More>---
NEO Stock 12 Month Forecast
Average Price Target
$17.78
▲(88.95% Upside)
Technical Analysis
Best Analysts Covering NEO
1 Year
1 Year Success Rate
6/14 ratings generated profit
1 Year Average Return
+3.99%
reiterated a buy rating 9 days ago
Copying David Westenberg's trades and holding each position for 1 Year would result in 42.86% of your transactions generating a profit, with an average return of +3.99% per trade.
---